Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HMPL-453 tartrate in FGFR2 fusion/rearrangement advanced intrahepatic cholangiocarcinoma
CTR20201011Phase 2Active
- Sponsor
- HUTCHMED
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fanregratinib in intrahepatic cholangiocarcinoma (ICC), sponsored by HUTCHMED. Started Sep 2020; status: active.
02
Drugs
fanregratinib
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on CTR20201011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201011.